Status:
COMPLETED
Short Course Glucocorticoid Treatment for PTSD
Lead Sponsor:
University of Wisconsin, Madison
Conditions:
Post-traumatic Stress Disorder
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to investigate if a 2-wk course of 20mg/day of oral prednisone in addition to standard care will result in reduced PTSD symptoms or symptom severity compared to placebo
Eligibility Criteria
Inclusion
- Must meet Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria for PTSD w/ symptom exacerbation (CAPS score ≥ 50)
- Stable on other psychotropic meds x1 month
Exclusion
- Current or past history of bipolar, schizophrenic, or other psychotic disorder
- Organic mental disorder
- Alcohol or substance abuse in last 3 months
- Clinically significant hepatic or renal disease or other acute or unstable medical condition
- Chronic obstructive pulmonary disease (COPD), asthma, uncontrolled diabetes, rheumatologic diseases
Key Trial Info
Start Date :
December 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2009
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00204737
Start Date
December 1 2004
End Date
January 1 2009
Last Update
May 6 2020
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Catherine Johnson
Madison, Wisconsin, United States, 53711
2
Wm. S. Middleton VA Hospital
Madison, Wisconsin, United States, 53711